Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Federal Trade Commission
Chinese Patent Office
Queensland Health
Baxter
Johnson and Johnson

Generated: September 18, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021518

  Try a free trial


See Plans and Pricing

« Back to Dashboard

NDA 021518 describes VESICARE, which is a drug marketed by Astellas and is included in one NDA. It is available from five suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the VESICARE profile page.

The generic ingredient in VESICARE is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.
Summary for 021518
Tradename:VESICARE
Applicant:Astellas
Ingredient:solifenacin succinate
Patents:1
Pharmacology for NDA: 021518
Medical Subject Heading (MeSH) Categories for 021518
Suppliers and Packaging for NDA: 021518
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VESICARE solifenacin succinate TABLET;ORAL 021518 NDA A-S Medication Solutions 50090-0972 50090-0972-0 30 TABLET, FILM COATED in 1 BOTTLE (50090-0972-0)
VESICARE solifenacin succinate TABLET;ORAL 021518 NDA Astellas Pharma US, Inc. 51248-150 51248-150-01 30 TABLET, FILM COATED in 1 BOTTLE (51248-150-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Nov 19, 2004TE:ABRLD:Yes
Patent:  Try a Free TrialPatent Expiration:May 19, 2019Product Flag?Substance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Nov 19, 2004TE:ABRLD:Yes
Patent:  Try a Free TrialPatent Expiration:May 19, 2019Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 021518

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas VESICARE solifenacin succinate TABLET;ORAL 021518-001 Nov 19, 2004   Try a Free Trial   Try a Free Trial
Astellas VESICARE solifenacin succinate TABLET;ORAL 021518-002 Nov 19, 2004   Try a Free Trial   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Deloitte
Colorcon
Johnson and Johnson
Federal Trade Commission
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.